X-linked hypophosphatemia


Also found in: Acronyms, Wikipedia.

X-linked hypophosphatemia

A type of rickets caused by genetic factors which prevent the kidneys from retaining phosphate.
Mentioned in: Rickets
Mentioned in ?
References in periodicals archive ?
and Europe: Crysvita[R]), we obtained approval of indication with conditions on sale for treatment of X-linked hypophosphatemia in pediatric patients in Europe, in February.
X-linked hypophosphatemia: dental and histologic findings.
Carpenter, M.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues randomized 52 children with X-linked hypophosphatemia to receive subcutaneous burosumab every two weeks or every four weeks in an open-label, phase 2 trial.
Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease.
However, several novel regulators of phosphate homeostasis have been identified as being associated with hypophosphatemia of various types, such as tumor-induced osteomalacia, several hereditary forms of hypophosphatemic rickets, X-linked hypophosphatemia, and autosomal dominant hypophosphatemia (1, 3).
Recombinant growth hormone therapy for X-linked hypophosphatemia in children.
(5) Often the clinical presentation mimics X-linked hypophosphatemia (XLH) or hereditary autosomal dominant hypophosphatemic rickets (ADHR).
Crysvita was approved by the FDA for the treatment of X-linked hypophosphatemia in adult and pediatric patients one year of age and older.
Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH).

Full browser ?